Table 3. Results of HI assays using Re-5 antiserum and Re-6 antiserum for avian influenza A(H5N1) isolated from tigers in Yunnan China, 2014–2015*.
| Isolate | Isolation date | HI titer ± SD, log2 | |
|---|---|---|---|
| Re-5 antiserum | Re-6 antiserum | ||
| A/tiger/Yunnan/Tig1404/2014 | 2014 Apr | 4.825 ± 1.083 | 4.475 ± 1.753 |
| A/tiger/Yunnan/Tig1412/2014 | 2014 Dec | 4.289 ± 1.160 | 6.75 ± 0.840 |
| A/tiger/Yunnan/Tig1508/2015 | 2015 Aug | 4.232 ± 1.212 | 3.675 ± 1.163 |
| A/peacock/Yunnan/1/2015 | 2015 Jun | 4.116 ± 1.141 | 3.525 ± 1.339 |
| Re-6 diagnostic antigen† | NA | 4.245 ± 1.791 | 8.875 ± 1.090 |
| Re-5 diagnostic antigen† | NA | 7.250 ± 0.909 | 5. 375 ± 1.330 |
*Re-5 (n = 38) and Re-6 (n = 40) antiserum were generated by vaccinating specific-pathogen free chickens with the commercial Re-5 and Re-6 vaccine (Harbin Weike biologic Technology Development Company, Harbin, China). HI titers against the homologous antigen/virus are shown in boldface. HI, hemagglutination inhibition; NA, not applicable. The titre differences were statistically significant by One Way ANOVA (P < 0.05).
†The commercial Re-5 and Re-6 diagnostic antigen (including positive and negative control serum) are from Harbin Weike biologic Technology Development Company, Harbin, China.